Ok, before everyone jumps on the "worthless PR" bandwagon,

New Post Public Reply Private Reply Replies (0) Message Board
barcode27
Ok, before everyone jumps on the "worthless PR" bandwagon, let's stop and think about what we can learn from today's news. The company has formally submitted a request for a pre-IND meeting to the FDA. This is a "Type B" meeting as defined in this guidance document:

www.fda.gov/downloads/Drugs/Guidances/ucm153222.pdf

Here's what it says regarding Type B meetings:

"Type B meetings should be scheduled to occur within 60 days of FDA receipt of the written meeting request."

Translation: The company will most likely be sitting face-to-face with the FDA within the next 60 days, unless the meeting is denied for a "substantive" reason (see page 5 of the document).

"Timing of Submission
A meeting package should be submitted to the appropriate review division so that it is received in accordance with the following time frames:
Type B meeting — At least 4 weeks before the formal meeting."

Translation: The company will most likely be providing detailed information on their proposed Eltoprazine trial to the FDA via a meeting package within the next ~30 days (60 day scheduling window minus 4 week submittal deadline)

And what exactly will be in the information package?

"Meeting packages generally should include the following information:
1. Product name and application number (if applicable).
2. Chemical name and structure.
3. Proposed indication.
4. Dosage form, route of administration, and dosing regimen (frequency and duration).
5. An updated list of sponsor or applicant attendees, affiliations, and titles.
6. A background section that includes the following:
a. A brief history of the development program and the events leading up to the meeting.
b. The status of product development (e.g., the target indication for use).
7. A brief statement summarizing the purpose of the meeting.
8. A proposed agenda.
9. A list of the final questions for discussion grouped by discipline and with a brief summary for each question to explain the need or context for the question.
10. Data to support discussion organized by discipline and question. For example, for an end-of-phase 2 meeting, this section should include the following, if not already provided in the background section (refer to item #6 above): description and results of controlled trials conducted to determine dose-response information; adequately detailed descriptors of planned phase 3 trials identifying major trial features such as trial population, critical exclusions, trial design (e.g., randomization, blinding, choice of control group, with explanation of the basis for any noninferiority margin if a noninferiority trial is used), choice of dose, primary and secondary trial endpoints; and major analyses (including planned interim analyses and adaptive features, and major safety concerns)."

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 233

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 165

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 311

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 182

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 238

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 162

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 213

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Investment by BrainsWay to Enhance Mental Health Solutions

Updated Category News Views 247

BrainsWay's Expansion Plans and Strategic Investment This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home. Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, and if granted, it will set a precedent as the first FDA-cleared medical...

Continue Reading
Mary Street Capital: Enhancing Investment Banking Services

Updated Category News Views 300

Mary Street Capital: A New Era in Investment Banking Mary Street Capital has emerged as an innovative investment banking affiliate of Kaufman Rossin, significantly expanding its advisory capabilities. This new venture focuses on addressing the unique needs of family- and founder-owned businesses, particularly those in the middle market that have often felt overlooked by...

Continue Reading
Fluorine-18 Market Growth Driven by Cancer Diagnosis Demand

Updated Category News Views 169

Fluorine-18 Market Growth Context The global fluorine-18 market is on a notable trajectory of growth, anticipated to reach USD 2.54 billion by 2031 from USD 1.85 billion in 2024. This progression is largely influenced by the increasing incidence of cancer and the expanding utilization of nuclear imaging methodologies. The Role of Fluorine-18 in Medical Diagnostics...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 227

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Chargeback Rates Increase Dramatically Amid Visa Changes

Updated Category News Views 320

Surge in Chargebacks Signals Major Industry Changes CLEVELAND — The payments industry is witnessing a seismic shift, with chargebacks soaring by an astonishing 222% year over year. This significant rise has impacted various sectors, including eCommerce, travel, subscription services, and healthcare. Understanding Visa's VAMP Program As Visa introduces its new Acquirer...

Continue Reading